Hjem › Kardiomyopati › California
Kliniske studier for Kardiomyopati i California
14 studier for Kardiomyopati søker deltakere på steder i California.
Byer i California
Offisiell studietekst (engelsk)
A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy
- University of California, San Diego, San Diego
RekruttererFase 1
Alder 18 til 65 · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07137338TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Clinical Trial Site, La Jolla
- Clinical Trial Site, Laguna Hills
- Clinical Trial Site, Stanford
RekruttererFase 3
Alder 18 til 85 · Alle kjønn · Oppdatert 16. sep. 2026 · NCT07052903DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting
- Clinical Trial Site, Beverly Hills
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2026 · NCT07358078Clinical Course Of Disease In Participants With FA-CM
- University of California San Diego, La Jolla
RekruttererObservasjonsstudie
Alder 6 og eldre · Alle kjønn · Oppdatert 2. sep. 2026 · NCT06865482Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
- Lucile Packard Children's Hospital, Palo Alto
RekruttererFase 2
Alder 0 til 16 · Alle kjønn · Oppdatert 10. aug. 2026 · NCT06080074Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- University of California, San Diego (UCSD) - Medical Center, La Jolla
- University of California, Los Angeles (UCLA) - David Geffen School of Medicine, Los Angeles
- University of California, San Francisco (UCSF), San Francisco
- og 1 flere
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 4. aug. 2026 · NCT06563895Danon Disease Natural History Study
- University of California, San Diego, La Jolla
RekruttererObservasjonsstudie
Alder 8 og eldre · Alle kjønn · Oppdatert 28. jul. 2026 · NCT06214507Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials
- UC Davis, Sacramento
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. jul. 2026 · NCT07674758The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients
- UCLA Cardiac Arrthmia Center, Los Angeles
- University of California San Francisco, San Francisco
RekruttererFase 4
Alder 18 og eldre · Alle kjønn · Oppdatert 14. jul. 2026 · NCT05034432A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease
- University of California, San Diego, La Jolla
RekruttererFase 2
Alder 8 og eldre · Menn · Oppdatert 4. mai 2026 · NCT06092034MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
- Cedars-Sinai Medical Center, Los Angeles
- Western Greater Los Angeles VA Medical Center, Los Angeles
- Stanford University, Palo Alto
- og 1 flere
RekruttererFase 3
Alder 18 til 90 · Alle kjønn · Oppdatert 27. mar. 2026 · NCT06128629A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM
- Leland Stanford Junior University, Redwood City
RekruttererObservasjonsstudie
Alder 18 til 65 · Alle kjønn · Oppdatert 16. mai 2025 · NCT06976606Large Language Models To Improve the Quality of Care of Cardiology Patients
- Stanford, Palo Alto
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 15. mai 2025 · NCT06935253Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions
- Southern California Hospital at Culver City / Southern California Hospital at Hollywood / Multiple US-based Sub-Investigator Sites, Culver City
RekruttererFase 1/2Frivillige helsepersonell ønskes velkommen
Alder 18 og eldre · Alle kjønn · Oppdatert 29. apr. 2022 · NCT04684602Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.